Fondaparinux, a factor Xa inhibitor, demonstrates efficacy and safety comparable to traditional options such as unfractionated heparin and low-molecular-weight heparin for the treatment of VTE.
Do factor Xa inhibitors (such as fondaparinux) provide comparable efficacy and safety to traditional anticoagulants in patients with venous thromboembolism?
Fondaparinux is an effective and safe alternative to traditional anticoagulants for the treatment of venous thromboembolism.
Anticoagulation is an essential component of the care of patients with venous thromboembolism (VTE). Traditional anticoagulants for the treatment of VTE include unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and the oral vitamin K antagonist, warfarin. A variety of anticoagulant agents with improved pharmacologic and clinical profiles are emerging and offer benefits over the traditional therapies. One of the most recent advances has been the development of new agents, such as oral direct thrombin inhibitors and factor Xa inhibitors, that have a more selective and targeted effect on the coagulation cascade. Recent clinical trials have evaluated fondaparinux, the first commercially available factor Xa inhibitor, in the treatment of patients with deep vein thrombosis and pulmonary embolism and indicate efficacy and safety as compared with traditional options such as UFH and LMWH. Fondaparinux is a welcomed addition to the available antithrombotic options.
Nutescu et al. (Thu,) conducted a review in Venous thromboembolism (VTE). Factor Xa inhibitors (e.g., fondaparinux) vs. Traditional anticoagulants (UFH, LMWH, warfarin) was evaluated. Fondaparinux, a factor Xa inhibitor, demonstrates efficacy and safety comparable to traditional options such as unfractionated heparin and low-molecular-weight heparin for the treatment of VTE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: